Runs a chain of paediatric and maternity hospitals in India under a hub-and-spoke model, where larger tertiary hubs feed smaller spoke units in the same city. As of the latest reported quarter it operates 24 hospitals across 9 cities with 2,565 beds and 1,075-plus doctors, and is extending to Western India with a 100-bed greenfield in Malad, Mumbai (due Q1 FY28). Revenue is earned from in-patient admissions, out-patient consultations, deliveries and paediatric intensive/quaternary care such as ECMO, with Q1 FY27 revenue of ₹470 cr (+33% YoY) on IP discharges +28%, OP consultations +25% and deliveries +23%, at an ARPOB of ₹67,256 and occupancy above 41%. The medium-term plan adds 2,500 beds over five years to reach 5,000 beds, of which 1,200 are already under execution, funded by an estimated ~₹2,100 cr of capex. Q1 FY27 EBITDA margin was 28.6%, with management guiding to 24–25% by year-end as newly commissioned hospitals ramp up. The biggest cost line is other operating expenses at 41.0% of revenue (FY26), followed by employee costs at 13.7% and materials at 13.3%, with depreciation at 8.8% and capex at 12.7%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. In-patient paediatric and maternity admissions, Out-patient consultations and clinic visits. Asset-heavy, capacity-expanding paediatric and maternity hospital chain with a hub-and-spoke template
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 974 | 1,174 | 1,297 | 1,516 | 1,703 |
| EBITDA (ex other income) | 305 | 396 | 429 | 490 | 543 |
| margin % | 31.3 | 33.8 | 33.1 | 32.3 | 31.9 |
| Owners' profit | 138 | 211 | 217 | 243 | 278 |
| EPS, as reported (₹) | 14.75 | 20.89 | 21.38 | 23.97 | 27.41 |
| ROE % · ROCE % | 22.9 · 20.5 | 19.9 · 20.6 | 17.3 · 17.5 | 16.6 · 18.1 | 16.9 · 16.8 |
| Debt / equity (x) | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 224 | 327 | 321 | 396 | 420 |
| Capex | (62) | (141) | (354) | (146) | (216) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 417 | 398 | 370 | 353 | 445 | 445 | 460 | 470 |
| Profit before tax | 105 | 94 | 77 | 71 | 102 | 98 | 87 | 84 |
| Net profit | 79 | 69 | 57 | 54 | 76 | 74 | 78 | 63 |
| EPS (₹) | 7.77 | 6.76 | 5.55 | 5.27 | 7.41 | 7.14 | 7.59 | 5.97 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Schedule of Analyst and Institutional Investor Meetings in Mumbai | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Chief Strategy Officer Srinath Metla resigns, effective Sept 5 | management changes | medium | — | — |
| 25 Aug 2026 · Chief Financial Officer Vikas Maheshwari resigns effective 31 August 2026 | management changes | high | — | — |
| 25 Aug 2026 · CFO Vikas Maheshwari resigns effective Aug 31, 2026 - personal reasons | management changes | high | — | — |
| 14 Aug 2026 · Rainbow Hospitals completes 64 percent acquisition of Super Prime Medical Care LLP | strategic transactions | high | — | — |
| 4 Aug 2026 · Q1 FY27 earnings call transcript; revenue up 33%, guides 20% growth | investor communications | medium | — | — |
| 31 Jul 2026 · Audio recording of Q1 FY27 earnings call available on website | investor communications | low | — | — |
| 31 Jul 2026 · Newspaper Publication of Q1 FY27 Financial Results | compliance | minimal | — | — |
| 30 Jul 2026 · Rainbow Hospitals Q1 FY27 revenue up 33%, plans Mumbai entry | investor communications | medium | — | — |
| 30 Jul 2026 · Rainbow Hospitals Q1 FY27 earnings revenue rises 33 percent YoY to Rs 470 cr | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 51.6 | 47.3 | 20 of 30 | 35% |
| P/B | 8.8 | 6.2 | 19 of 24 | 22% |
| ROCE | 13.8 | 10.9 | 8 of 30 | 76% |
| ROE | 16.9 | 11.8 | 6 of 24 | 78% |
| Debt / Equity | 0.0 | 0.2 | 1 of 24 | 91% |
| EBITDA margin | 31.4 | 22.0 | 3 of 24 | 91% |
| Revenue growth | 33.2 | 20.2 | 5 of 23 | 82% |
| Profit growth | 16.2 | 8.1 | 8 of 21 | 65% |
| Market cap | 14727 | 2415 | 9 of 30 | 72% |
| A rating (BUY / ADD / REDUCE / SELL) |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
